The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
Open accessAbstract
Sativex is a cannabis-plant extract delivering nearly 1:1 Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) by oromucosal spray. It has been suggested that CBD attenuates THC-induced tachycardia, anxiety, and euphoria. In this study, pharmacodynamic effects were compared over 10.5 h in nine cannabis smokers randomly assigned to receive placebo, 5 and 15 mg oral synthetic THC, and low (5.4 mg THC, 5.0 mg CBD) and high (16.2 mg THC, 15.0 mg CBD) doses of Sativex. At therapeutic doses, no substantial CBD-induced modulation of THC's effects was evident. Oral THC and Sativex produced similar, clinically insignificant increases in heart rate, anxiety, and "good drug effects" with no serious adverse events. Oral and oromucosal THC have slower absorption, lower rate of THC delivery to the brain, and fewer associated adverse events as compared with smoked cannabis. These results indicate that Sativex has a pharmacodynamic safety profile comparable to that of oral THC at low, therapeutic doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oral cannabinoids administration, on the other hand, avoids concentration peaks and with chronic administration, the individual differences in bioavailability are overcome [23, 33].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [33]
In the citing paper
“The oral administration of cannabinoid drugs shows poorer bioavailability than when these drugs are administered by inhalation.”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570
Ohlsson, A., Lindgren, J. ‐., Wahlén, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.181 · Cited by 475
Psychiatric effects of cannabis
Johns, A. R. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.2.116 · Cited by 468
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kei183 · Cited by 433
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
de Fonseca, F. R., del Arco, I., Bermúdez‐Silva, F. J., Bilbao, A., Cippitelli, A., & Navarro, M. (2004) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 419
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
Research works printed but not linked: 2
- Zuardi A.W., 1995, J. Clin. Psychiatry, 56, 485
- Sandyk R., 1986, Neurology, 36, 342
Cited by
Sorted by citations
Items 101–118 of 118
WITHDRAWN: The Endocannabinoid System: Overview of an Emerging Multi-faceted Therapeutic Target
Chanda, D., Neumann, D., & Glatz, J. F. C. (2018) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.07.004 · Cited by 2
RetractedPrescrire du cannabis fumé pour la douleur chronique non cancéreuse: Recommandations préliminaires
Kahan, M., Srivastava, A., Spithoff, S. M., & Bromley, L. A. (2014) · Europe PMC (PubMed Central)
Cannabinoids Pharmacology, Abuse, and Addiction
Huestis, M. A., & Smith, M. L. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6434-1_158-1
Self-citationSherman, C. (2018) · TSpace (University of Toronto)
(2018) · Journal of Nursing Regulation · doi:10.1016/s2155-8256(18)30088-7
de Freitas, & Alyson, L. (2020)
Cannabis in Palliative Medicine
Saint-Preux, F., Arora, A., Moriyama, D., Kim, E., & Kim, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-45968-0_13
Cardiovascular events post cannabis abuse during the COVID-19 pandemic
Kotsalou, I., Mantonanakis, G., Κότσαλος, Α., Koniaris, G., Zafeirakis, A. G., & Dimakopoulos, N. (2021) · Medical Science and Discovery · doi:10.36472/msd.v8i6.553
“According to recent reports, the CB use might also cause dose-dependent elevation of the systolic blood pressure and heart rate (18, 19) and induce atrial fibrillation shortly after smoking MJ (20).”
BackgroundRole of Cannabinoids in Pain Management
Russo, E. B., & Hohmann, A. G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1818-8_18
Appendix C: References (Part I)
(2018) · Journal of Nursing Regulation · doi:10.1016/s2155-8256(18)30100-5
Cannabinoids Pharmacology, Abuse, and Addiction
Huestis, M. A., & Smith, M. L. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3474-4_158
Self-citationHerrold, A., Aaronson, A., Bhaumik, D., Durazzo, T. C., Livengood, S., Ramić, A., Riordan, P., Jordan, N., Parrish, T., Mallinson, T., et al. (2024) · JMIR Research Protocols · doi:10.2196/64909
“Participants will also complete an acute cannabis intoxication scale [67] that includes four items: (1) increased resting heart rate (>100 beats per min), (2) congestion of the conjunctival blood vessels (red eyes), (3) slowed speech, and (4) giddiness.”
The Endocannabinoid System and Medicinal Cannabis
O’Brien, K., & Bosak, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-01737-6_2
Stress, Anxiety, and Depression
O’Brien, K., & Bosak, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-01737-6_3 · Cited by 1
The Relationship Between (Endo)cannabinoids, the Microbiome and Melanoma
Javid, F. A., Golčić, M., Harej, A., & Belančić, A. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70304
“Some clinical trials have also been carried out that led to the introduction of some cannabis-based drugs such as dronabinol, nabilone, nabiximol (sativex), and, more recently, epidiolex [15–18].”
Applikationswege, Pharmakokinetik und Sicherheit von medizinischem Cannabis
O’Brien, K., & Blair, P. (2026) · Springer eBooks · doi:10.1007/978-3-032-14521-5_11
Bagheri, F., Scherma, M., Murru, E., Contena, G., Banni, S., Argiolas, A., Melis, M. R., Fadda, P., & Sanna, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.742765
BindingDB Entry 50005878: Controlled-deactivation cannabinergic ligands.
BindingDB (2020) · UC San Diego · doi:10.7270/q241711q
Metadata
- Authors
- Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A.
- Affiliations
- National Institutes of Health (US)
- GW Pharmaceuticals (United Kingdom) (GB)
- Corresponding author
- Huestis, M A
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-02-02
- Volume
- 89
- Issue
- 3
- Pages
- 400-407
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- PMC
- PMC3836266
- OpenAlex
- W2143261008
- Cited by
- 117
- References
- 33
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 15 · 2021: 12 · 2020: 13 · 2019: 8 · 2018: 13 · 2017: 6 · 2016: 4 · 2015: 4 · 2014: 9 · 2013: 6 · 2012: 8
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (ZIADA000541)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- Sativex, cannabidiol, tetrahydrocannabinol, pharmacodynamics, heart rate, anxiety, euphoria, cannabis smoking, drug delivery routes, adverse events
- MeSH terms
- Administration, Oral, Adult, Anxiety, Brain, Cannabidiol, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Female, Heart Rate, Humans, Male, Mouth Mucosa, Plant Extracts, Psychotropic Drugs, Dronabinol, Tissue Distribution, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
